Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to ... with LaurelCo, LLC, an Illinois limited ... and dispensary medical marijuana licenses in the state of ... acquire a 20% equity interest in LaurelCo, LLC in exchange ... chambers, as well as all technology related to the machines ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Acsis Addresses Questions on the Modern Supply Chain 2
... 17 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) ... Oxygen Concentrate Gel to customers who have pre-ordered through ... today, cover orders received through early November. , "This ... actually shipping a product to customers and generating revenue ...
... , REYKJAVIK, Iceland, Nov. 17 deCODE ... has filed a voluntary petition for relief under Chapter 11 ... Bankruptcy Court for the District of Delaware to facilitate the ... to operate its business and manage its properties as a ...
Cached Medicine Technology:Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 3deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 4
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
(Date:7/25/2014)... As reported by the New Orleans Advocate ... (7/3), the state of Louisiana has recently seen a ... than cocaine. Officials believe the increase is due to a ... of marijuana. However, both doctors and police confirm that that ... to call it “poison,” doctors have acknowledged that the Louisiana ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... Houston, TX (PRWEB) July 25, 2014 ... Annual Family Fun Fest on Sunday, July 27 at ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, ... location in The Heights. , “We’re thrilled to ... this year,” said Heather Belcher who owns the Sugarland-Missouri ...
(Date:7/25/2014)... July 25, 2014 A new study conducted ... revealed that 39 percent of all children in the survey under ... The survey looked at 2,505 children during the years of 2011 ... years of age. The final result was that about two ... Many of these children were from lower-income families and were of ...
Breaking Medicine News(10 mins):Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... UCSF institute aimed at accelerating the pace of translating ... million from the National Institutes of Health to expand ... UCSF Clinical and Translational Science Institute (CTSI) is among ... recognition of their successes during the first five years ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay News) -- ... of mild cognitive impairment, a potential precursor of Alzheimer,s ... there may be a very high rate of cognitive ... general population in that age range," said lead researcher ...
... , FRIDAY, July 15 (HealthDay News) -- Although many people ... relationship between stress and alcohol is a two-way street, researchers ... stress, the authors of a new study pointed out. Meanwhile, ... individuals to drink more to produce the same effect. As ...
... (HealthDay News) -- Compared with older people with no signs of ... twice as likely to experience a fall, researchers have found. ... older adults who were participating in a study of memory and ... many times they fell over the course of eight months. ...
... 2011) Today at the 6th International AIDS ... Prevention, the Drugs for Neglected Diseases initiative (DNDi) ... programme to address critical unmet treatment needs of ... in young children has largely been eliminated in ...
... York University,s Department of Chemistry and NYU Langone Medical ... a protein implicated in many types of cancer. The ... journal Nature Chemical Biology. The ... RTK signaling is a major underlying cause of various ...
Cached Medicine News:Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 2Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 3Health News:Ex-NFL Players May Face Higher Brain Damage Risk, Study Says 4Health News: Drinking Alcohol May Prolong, Not Relieve, Stress 2Health News:Falls Could Signal Early Alzheimer's Disease 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 2Health News:DNDi launches new drug development program to address treatment needs of children with HIV/AIDS 3
... integrates drug infusion,with patient monitoring and ... modular platform. With multiple configuration,options, you ... you,need them, keeping the number of ... while managing the unique needs of,each ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... the first steps any hospital or health ... most powerful, most effective tools available for ... world-class clinician documentation and electronic medical record ... achieve this goal. In fact, its the ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
Medicine Products: